Prof Luminari speaks to ecancer about the long-term efficacy and survival outcomes with ordronextamab for patients with relapsed/refractory follicular lymphoma (R/R FL): 2-year follow-up from the phase 2 ELM-2 study.

This study reveals long-term efficacy data for treating follicular lymphoma with ordronextamab as a single agent.

It includes 128 patients with aggressive disease features, showing high activity and favourable response rates.

Updated findings indicate improved response rates and median progression-free survival, with manageable adverse events primarily being grade one or two CRS.

The study confirms no severe COVID cases linked to the treatment and supports further research into combination therapies.